RxDoctor Payments Data

Stacy Gajewski, MD

Family Medicine · Columbia, SCNPI 1467553404

Payments from drug & device makers

$5,055in general payments, 2019–2025

Across 320 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$582
  • AstraZeneca$504
  • Lilly USA, LLC$399
  • Novo Nordisk$365
  • Pfizer$321
  • GSK$230
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$4,97098%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,055 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$183,251
Medicare patients
491
Services billed
3,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$179,963
JardianceEmpagliflozin151$171,275
EliquisApixaban154$132,157
XifaxanRifaximin22$83,272
TrulicityDulaglutide47$69,636
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$53,738
Tresiba Flextouch U-200Insulin Degludec28$50,610
JanuviaSitagliptin Phosphate37$44,181
MounjaroTirzepatide41$43,862
FarxigaDapagliflozin Propanediol52$41,930
XareltoRivaroxaban21$30,064
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$27,123
LinzessLinaclotide20$26,590
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$20,454
EntrestoSacubitril/Valsartan16$18,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$365$179,963135 claims
Boehringer IngelheimJardiance$116$171,275151 claims
PfizerEliquis$321$132,157154 claims
Lilly USA, LLCTrulicity, Mounjaro$399$113,49788 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$98$83,27222 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$504$66,70789 claims
GSKTrelegy Ellipta$230$53,73837 claims
MerckJanuvia$99$44,18137 claims
Johnson & JohnsonXarelto$150$30,06421 claims
AbbVieLinzess$582$26,59020 claims
NovartisEntresto$105$18,66716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →